Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

Primary Analysis of Pivotal Trial to Be Available No Later Than July 2008

SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced that an independent Data Monitoring Board (DMB) was recently convened to assess time to tumor progression (TTP) for patients in the control group of the Company's pivotal Phase 3 clinical trial of FavId(R). The DMB assessment, which was conducted in accordance with the clinical protocol under Favrille's Special Protocol Assessment (SPA) with the Food & Drug Administration (FDA), indicated that the control group behavior is consistent with data reported in the published literature. Based in part on the guidance provided by the DMB, Favrille has determined April 2008 to be the appropriate time for data cutoff of the Phase 3 trial. The Company anticipates that the analysis of the data will be completed and made available no later than July 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

The Phase 3 trial is a randomized, double-blind, placebo controlled trial of FavId following Rituxan(R) treatment in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). A total of 349 patients were randomly assigned to receive either FavId plus Leukine(R) (sargramostim, GM-CSF) or placebo plus Leukine following a course of Rituxan treatment. The primary endpoint of this trial is TTP.

"As we previously communicated, the rate of progression in our pivotal Phase 3 trial has slowed during the past 12 months," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "We believe this is a positive development, and it has shifted our focus for data cutoff and analysis to trial follow-up time as allowed in the protocol rather than the number of patient progressi
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. 20, ... , the Canadian Medical Association (CMA) voted on and ... plant material, including medicinal cannabis. Bedrocan Cannabis Corp., a ... of the CMA motion. The CMA is ... hazards associated with smoking any plant material, including medicinal ...
(Date:8/22/2014)... COLUMBUS, Ohio , Aug. 22, 2014 MC ... Devices Inc. (MID), a Columbus, OH ... to distribute the FloShield laparoscopic and robotic visualization system in ... will be approved for sale in Japan ... has a long-time experience and an extensive product portfolio in ...
(Date:8/22/2014)... Research and Markets has announced ... Respirators Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced that it is scheduled to speak ... York City. The presentation is scheduled for Tuesday, September ... The presentation will be webcast live during the conference ...
... Sept. 8, 2011 Spherix Incorporated ... in biotechnology for therapy in diabetes, metabolic syndrome ... consulting services to food, supplement, biotechnology and pharmaceutical ... SPX-106, achieved statistically significant reductions in VLDL and ...
Cached Medicine Technology:SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 2SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 3
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
(Date:8/23/2014)... 2014 Pixel Film Studios, a leader of ... release of ProIntro Vol.3, a customizable title tool for ... tile just by dragging ProIntro Vol.3 in their timeline" says ... a definite time saver and i think our users will ... beautifully designed titles made with Final Cut Pro X users ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Teen drug ... Carolina. It’s no different in Wilmington, NC. Substance abuse ... are falling victim to drug and alcohol dependency in ... are looking to overcome substance abuse, but don’t know ... adolescent treatment facility can be a challenge because most ...
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is ... several years. He has recently announced that GoDaddy ( ... in 2014. , GoDaddy is a popular supplier of ... great hosting solutions at affordable rates. It offers three ... hosting plans depend on the length of the contract. ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online ... Health Plans. , According to Zane Benefits, employers are ... lower the cost of healthcare without reducing coverage for ... however, can be confusing. , The new guide contains ... main types of ABHPs. It also explains the ...
Breaking Medicine News(10 mins):Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... News) -- The prevalence of psoriasis -- a chronic, inflammatory ... and obese kids, researchers have found. The Kaiser ... , also found that teens with psoriasis (regardless of their ... risk for heart disease. "This study suggests a ...
... 20 (HealthDay News) -- For the average listener, the ... speaker,s sexual orientation, a new study finds. "I,m not ... vowel," study lead author Erik C. Tracy, a cognitive psychologist ... the American Institute of Physics. "Other researchers have done various ...
... , FRIDAY, May 20 (HealthDay News) -- All ... to 11 years old, according to new guidelines from the ... with a family history of premature cardiovascular disease or elevated ... as early as age 2. "It,s important that people ...
... Dr. Jeffrey M. Trent, F.A.C.M.G., a nationally recognized ... has been appointed Foreign Trade Counselor of Luxembourg in ... and Research Director of the Translational Genomics Research Institute ... Grand Rapids, Michigan. Both non-profit biomedical research institutes study ...
... News) -- Though a new study suggests that a dietary ... develop preeclampsia, the jury is still out over whether it ... it yet. Preeclampsia is a pregnancy complication ... hypertension. It affects about 5 percent of first pregnancies. ...
... SESSION I / Monday, May 23 / 8 ... Acute Coronary Syndrome Patients in Real World Clinical Practice: Observations ... Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, Kern DM1, ... SESSION II / Tuesday, May 24 / 8 ...
Cached Medicine News:Health News:Study Sees Link Between Psoriasis, Obesity in Kids 2Health News:Straight or Gay? Vowels in Speech May Give it Away 2Health News:Experts Say Cholesterol Screenings Should Start in Childhood 2Health News:TGen/VARI president Dr. Jeffrey Trent appointed Foreign Trade Counselor by Luxembourg 2Health News:Study Suggests Supplement May Protect Against Preeclampsia 2Health News:HealthCore presents ISPOR poster sessions 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: